Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GNPX |
---|---|---|
09:32 ET | 559 | 2.2332 |
09:43 ET | 105 | 2.25 |
09:50 ET | 100 | 2.2078 |
10:01 ET | 1522 | 2.2404 |
11:24 ET | 2500 | 2.2699 |
11:44 ET | 100 | 2.25 |
12:07 ET | 100 | 2.22 |
12:16 ET | 2700 | 2.24 |
12:18 ET | 247 | 2.27 |
12:20 ET | 2500 | 2.25 |
12:48 ET | 100 | 2.25 |
01:03 ET | 1975 | 2.25 |
01:08 ET | 3250 | 2.23 |
01:15 ET | 100 | 2.23 |
02:02 ET | 100 | 2.26 |
02:24 ET | 100 | 2.23 |
02:42 ET | 4057 | 2.235 |
02:51 ET | 500 | 2.19 |
02:54 ET | 1655 | 2.1613 |
03:02 ET | 100 | 2.18 |
03:39 ET | 2740 | 2.13 |
03:56 ET | 100 | 2.12 |
03:59 ET | 200 | 2.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Genprex Inc | 4.4M | -0.1x | --- |
Artelo Biosciences Inc | 4.4M | -0.4x | --- |
GB Sciences Inc | 4.5M | -1.0x | --- |
Cingulate Inc | 4.4M | 0.0x | --- |
Alterola Biotech Inc | 4.5M | -1.2x | --- |
Mymd Pharmaceuticals Inc | 4.6M | -0.4x | --- |
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.63 |
EPS | $-19.18 |
Book Value | $4.99 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.